Abandoning clinical trial safeguards won’t boost local industry
Access status:
Open Access
Type
ArticleAbstract
Testing new drugs in clinical trials is a billion-dollar industry in Australia, with most of the money coming from international pharmaceutical companies. But as investment grows in India, China, and other emerging competitors, some people argue we need to make Australia more attractive to such investment. One of their solutions is to water down the ethics approval process.Testing new drugs in clinical trials is a billion-dollar industry in Australia, with most of the money coming from international pharmaceutical companies. But as investment grows in India, China, and other emerging competitors, some people argue we need to make Australia more attractive to such investment. One of their solutions is to water down the ethics approval process.
See less
See less
Date
2013-10-07Publisher
The ConversationCitation
Komesaroff P, Thomson C, Kerridge I, (2013) Abandoning clinical trial safeguards won’t boost local industry, The ConversationShare